Effectiveness of lenalidomide in relapsed primary cutaneous diffuse large B‐cell lymphoma, leg type.

Authors :: Al Dhafiri, Mahdi
Sicre de Fontbrune, Flore
Marinho, Eduardo
Deschamps, Lydia
Di‐Lucca, Julie
Crickx, Beatrice
Descamps, Vincent
Source :: Clinical Case Reports; May2019, Vol. 7 Issue 5, p964-967, 4p
Publication Year :: 2019
Abstract: Key Clinical Message: The primary cutaneous diffuse large B‐cell lymphoma, leg type (PCDLBCL‐LT) has a poor prognosis. R‐CHOP with or without radiotherapy is the available recommendations for first‐line treatment. Relapses/refractory cases are frequent with no standardized therapeutic guidelines. Lenalidomide seems to be an excellent therapeutic option as a second‐line treatment of relapsed PCDLBCL‐LT. [ABSTRACT FROM AUTHOR]

Subjects :: LYMPHOMAS
DIFFUSE large B-cell lymphomas
LEG
THERAPEUTICS
RADIOTHERAPY
PROGNOSIS

Full Text Access

Tools